Cargando…
Cellular responses at the application site of a high-density microarray patch delivering an influenza vaccine in a randomized, controlled phase I clinical trial
Microarray patches (MAPs) have the potential to be a safer, more acceptable, easier to use and more cost-effective method for administration of vaccines when compared to the needle and syringe. Since MAPs deliver vaccine to the dermis and epidermis, a degree of local immune response at the site of a...
Autores principales: | Depelsenaire, Alexandra C. I., Witham, Katey, Veitch, Margaret, Wells, James W., Anderson, Christopher D., Lickliter, Jason D., Rockman, Steve, Bodle, Jesse, Treasure, Peter, Hickling, Julian, Fernando, Germain J. P., Forster, Angus H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323919/ https://www.ncbi.nlm.nih.gov/pubmed/34329337 http://dx.doi.org/10.1371/journal.pone.0255282 |
Ejemplares similares
-
Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial
por: Forster, Angus H., et al.
Publicado: (2020) -
A chimeric dengue virus vaccine candidate delivered by high density microarray patches protects against infection in mice
por: Choo, Jovin J. Y., et al.
Publicado: (2021) -
M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP)
por: Mills, Jamie-Lee S., et al.
Publicado: (2020) -
Author Correction: M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP)
por: Mills, Jamie-Lee S., et al.
Publicado: (2020) -
Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial
por: Baker, Ben, et al.
Publicado: (2023)